Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Completed
Trial end date:
2018-01-19
Target enrollment:
Participant gender:
Summary
To assess the potential efficacy (in terms of objective response) of single agent copanlisib
in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the
relationship between efficacy and a potentially predictive biomarker